AstraZeneca

Selected news for the company - AstraZeneca, collected since 4/2019. This company shares news with COVID-19, COVID-19 Vaccine, Pfizer, Coronavirus, Moderna and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - The Cerbat Gem thecerbatgem.com ... average trading volume of 4,950,000 shares, the days-to-cover ratio is presently 1.3 days.AZN has been the subject of several research reports. SVB Leerink reissued a “buy” rating on shares of AstraZeneca in a report on Sunday, December 12th. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating and set a $54.00 price target for the company. in a report on ...
1/12/2022 AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - Watch List News watchlistnews.com ... the November 30th total of 7,550,000 shares. Based on an average daily trading volume, of 4,950,000 shares, the short-interest ratio is presently 1.3 days.Shares of AZN stock opened at $58.10 on Wednesday. AstraZeneca has a 12 month low of $46.48 and a 12 month high of $64.21. The firm has a market cap of $180.01 billion, a PE ratio of 90.78, a price-to-earnings-growth ratio of ...
1/12/2022 Covid Valencia vaccine | The Clinic seeks volunteers for the clinical trial of the Spanish vaccine archynewsy.com The Hospital Clínico de Valencia seeks volunteers to participate in the clinical trial of the HIPRA Covid-19 Vaccine Phase III, as they have indicated from the hospital center.To participate in the study, volunteers must have received at least one vaccine AstraZeneca , Janssen , Pfizer The Modern or have passed the covid sometime.Interested persons must fill out a form and send an email to [[email protected]](/cdn-cgi ...
1/12/2022 Advisory Services Network LLC Has $467,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) thelincolnianonline.com Advisory Services Network LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 14.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,771 shares of the company’s stock after purchasing an additional 1,006 shares during the period. Advisory Services Network LLC’s holdings in AstraZeneca were worth $467,000 at the end of the most recent reporting period.Several ...
1/12/2022 JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor | FierceBiotech FierceBiotech ... action is wrapped here . We'll finish off the event with another compilation of our stories on Thursday's Day 4.UPDATED: Wednesday 10:33 a.m. ETFlush with $2 billion in cash and recent partnerships with AstraZeneca and Biogen , Ionis Pharmaceuticals expects to have a “tidal wave of drugs” reaching the market by 2030, said Brett Monia , Ph.D., CEO and cofounder, at the annual J.P. Morgan Healthcare Conference. The pharma will ...
1/12/2022 Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development FierceBiotech ... partnered melanoma drug Zelboraf. With a few candidates in phase 1 and more prospects in preclinical, Plexxikon was looking to repeat its successes.Daiichi’s focus has shifted, though. Today, Daiichi sees its two AstraZeneca -partnered ADCs, Enhertu and datopotamab deruxtecan, along with the wholly owned patritumab deruxtecan as the priority programs. The three ADCs form one of the four strategic pillars in Daiichi’s five-year business plan.That ...
1/12/2022 AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US FiercePharma Order up. Shortly after topping off supplies of COVID-19 drugs from Pfizer and GlaxoSmithKline, the U.S. has asked for a second helping of AstraZeneca ’s antibody combo.The government has purchased an additional 500,000 doses of AZ’s long-acting antibody cocktail Evusheld, or tixagevimab plus cilgavimab. That comes on top of 700,000 doses the U.S. already ordered, for a total supply of 1.2 million, the British drugmaker said ...
1/12/2022 Letter to Graham Brady on Leaky Vaccines and AstraZeneca Monkey Trials gumshoenews.com by Elizabeth HartIt’s now known the covid-19 injections are ‘leaky vaccines’ that don’t prevent infection nor transmission. It’s claimed they provide dubious ‘protection’ of limited duration. But most people weren’t in need of this ‘protection’ as they weren’t at serious risk of Covid-19.Now billions of people around the world, including children, are being set up for repeat shots ...
1/11/2022 The telemedicine platform to decide the growth parameters of the Injectable Suspensions Market lakeshoregazette.com ... suspensions market is majorly driven by the rising prevalence of chronic diseases, acquisition and mergers between the companies, benefits of injectable suspensions, and approvals from the government authorities.For instance, in 2017, FDA approved AstraZeneca ’s injectable suspensions, Bydureon BCise, for the treatment of type 2 diabetes. Moreover, an increase in the awareness about the injectable suspensions and R & D investment by the companies for improving the product pipeline is ...
1/11/2022 Short Interest in AstraZeneca PLC (NASDAQ:AZN) Declines By 16.8% - Mayfield Recorder Mayfield Recorder ... 7,550,000 shares. Based on an average daily trading volume, of 4,950,000 shares, the days-to-cover ratio is presently 1.3 days.Several research analysts have weighed in on AZN shares. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating and set a $54.00 target price on the stock. in a research note on Tuesday, December 7th. UBS Group restated a “buy” rating on ...
1/11/2022 Short Interest in AstraZeneca PLC (NASDAQ:AZN) Declines By 16.8% - Slater Sentinel slatersentinel.com ... 200 day moving average price of $58.51. The company has a market cap of $179.33 billion, a P/E ratio of 90.44, a P/E/G ratio of 0.97 and a beta of 0.51. AstraZeneca has a one year low of $46.48 and a one year high of $64.21.Get AstraZeneca alerts: AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 11th. The company reported $0.54 earnings ...
1/11/2022 3 drugs to watch in early 2022 Becker's Hospital Review ... tezepelumab, a treatment for severe asthma, Dec. 17. The drug works by blocking specific molecules that affect airway inflammation. The drug has a broad indication and can be used for a large patient population. AstraZeneca and Amgen developed the drug, which goes by the brand name Tezspire.2. Cabotegravir. This drug is intended for use as a pre-exposure prophylaxis for individuals at high-risk of contracting HIV-1. While ...
1/11/2022 Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development tncontentexchange.com Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific AntibodyHAMILTON, Ontario and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company's collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). Both companies will jointly develop through a Phase ...
1/11/2022 Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development tncontentexchange.com Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific AntibodyHAMILTON, Ontario and BOSTON, Jan. 10, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company's collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). Both companies will jointly develop through a Phase ...
1/11/2022 AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Meeder Asset Management Inc. baseballnewssource.com Meeder Asset Management Inc. boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 714.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,292 shares of the company’s stock after acquiring an additional 2,888 shares during the period. Meeder Asset Management Inc.’s holdings in AstraZeneca were worth $198,000 at the end of the most recent reporting period.A number ...
1/11/2022 South Dakota Investment Council Grows Stake in AstraZeneca PLC (NASDAQ:AZN) - Ticker Report Ticker Report South Dakota Investment Council increased its position in AstraZeneca PLC (NASDAQ:AZN) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 138,470 shares of the company’s stock after purchasing an additional 3,095 shares during the period. South Dakota Investment Council’s holdings in AstraZeneca were worth $8,317,000 at the end of the most ...
1/11/2022 South Dakota Investment Council Buys 3,095 Shares of AstraZeneca PLC (NASDAQ:AZN) Daily Political South Dakota Investment Council grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 138,470 shares of the company’s stock after purchasing an additional 3,095 shares during the quarter. South Dakota Investment Council’s holdings in AstraZeneca were worth $8,317,000 as of its most recent SEC filing ...
1/11/2022 Fusion nominates first targeted alpha therapy under AstraZeneca partnership clinicaltrialsarena.com Fusion Pharmaceuticals has nominated the first targeted alpha therapy (TAT) candidate under its partnership agreement with AstraZeneca to commence Phase I clinical trials.The companies will co-develop the new TAT through a Phase I trial.The new TAT leverages the Fast-Clear linker technology of Fusion to radiolabel an AstraZeneca-owned bispecific antibody with actinium-225 alpha-emitting isotope.According to the prior partnership agreement, Fusion will handle the ...
1/11/2022 Alaska Permanent Fund Corp Purchases New Position in AstraZeneca PLC (NASDAQ:AZN) rivertonroll.com Alaska Permanent Fund Corp purchased a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 30,590 shares of the company’s stock, valued at approximately $1,837,000.A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. OLD Mission Capital LLC bought a new position in AstraZeneca in the 3rd quarter valued at about $7,581,000 ...
1/11/2022 Thornburg Investment Management Inc. Purchases 4,597 Shares of AstraZeneca PLC (NASDAQ:AZN) dispatchtribunal.com Thornburg Investment Management Inc. lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 0.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 965,523 shares of the company’s stock after acquiring an additional 4,597 shares during the period. Thornburg Investment Management Inc.’s holdings in AstraZeneca were worth $57,989,000 at the end of the most recent ...